120 related articles for article (PubMed ID: 30587910)
1. Erratum: A Phase II/III, randomized, double-masked, vehicle-controlled, dose-ranging study of the safety and efficacy of OTX-101 in the treatment of dry eye disease [Corrigendum].
Clin Ophthalmol; 2018; 12():2637. PubMed ID: 30587910
[TBL] [Abstract][Full Text] [Related]
2. Erratum: A Phase II/III, randomized, double-masked, vehicle-controlled, dose-ranging study of the safety and efficacy of OTX-101 in the treatment of dry eye disease [Corrigendum].
Clin Ophthalmol; 2019; 13():215. PubMed ID: 30774301
[TBL] [Abstract][Full Text] [Related]
3. A Phase II/III, randomized, double-masked, vehicle-controlled, dose-ranging study of the safety and efficacy of OTX-101 in the treatment of dry eye disease.
Tauber J; Schechter BA; Bacharach J; Toyos MM; Smyth-Medina R; Weiss SL; Luchs JI
Clin Ophthalmol; 2018; 12():1921-1929. PubMed ID: 30323548
[TBL] [Abstract][Full Text] [Related]
4. A Phase 3, Randomized, Double-Masked Study of OTX-101 Ophthalmic Solution 0.09% in the Treatment of Dry Eye Disease.
Goldberg DF; Malhotra RP; Schechter BA; Justice A; Weiss SL; Sheppard JD
Ophthalmology; 2019 Sep; 126(9):1230-1237. PubMed ID: 30965064
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of OTX-101, a Novel Nanomicellar Formulation of Cyclosporine A, for the Treatment of Keratoconjunctivitis Sicca: Pooled Analysis of a Phase 2b/3 and Phase 3 Study.
Sheppard J; Kannarr S; Luchs J; Malhotra R; Justice A; Ogundele A; Darby C; Bacharach J
Eye Contact Lens; 2020 Jan; 46 Suppl 1():S14-S19. PubMed ID: 31361655
[TBL] [Abstract][Full Text] [Related]
6. Effect of OTX-101, a Novel Nanomicellar Formulation of Cyclosporine A, on Conjunctival Staining in Patients with Keratoconjunctivitis Sicca: A Pooled Analysis of Phase 2b/3 and 3 Clinical Trials.
Smyth-Medina R; Johnston J; Devries DK; Jasper A; Kannarr SR; Schechter BA; Shen Lee B; Varghese G; Ogundele A; Darby CH; Karpecki P; Luchs J
J Ocul Pharmacol Ther; 2019 Sep; 35(7):388-394. PubMed ID: 31373837
[No Abstract] [Full Text] [Related]
7. Corrigendum.
Paediatr Child Health; 2015; 20(8):466-7. PubMed ID: 26744561
[TBL] [Abstract][Full Text] [Related]
8. ERRATUM.
Int J Bioprint; 2020; 6(4):309. PubMed ID: 33102924
[TBL] [Abstract][Full Text] [Related]
9. Erratum: Ocular comfort assessment of lifitegrast ophthalmic solution 5.0% in OPUS-3, a Phase III randomized controlled trial [Corrigendum].
Clin Ophthalmol; 2018; 12():913. PubMed ID: 29845978
[TBL] [Abstract][Full Text] [Related]
10. Erratum: BP-C1 in the treatment of patients with stage IV breast cancer: a randomized, double-blind, placebo-controlled multicenter study and an additional open-label treatment phase [Corrigendum].
Breast Cancer (Dove Med Press); 2015; 7():163. PubMed ID: 26170717
[TBL] [Abstract][Full Text] [Related]
11. Erratum: Morning and evening efficacy evaluation of rupatadine (10 and 20 mg), compared with cetirizine 10 mg in perennial allergic rhinitis: a randomized, double-blind, placebo-controlled trial [Corrigendum].
J Asthma Allergy; 2015; 8():135-7. PubMed ID: 26719714
[TBL] [Abstract][Full Text] [Related]
12. A Phase II, Multicenter, Randomized, Placebo-Controlled, Double-Masked Trial of a Topical Estradiol Ophthalmic Formulation in Postmenopausal Women with Moderate-to-Severe Dry Eye Disease.
Schmidl D; Szalai L; Kiss OG; Schmetterer L; Garhöfer G
Adv Ther; 2021 Apr; 38(4):1975-1986. PubMed ID: 33710587
[TBL] [Abstract][Full Text] [Related]
13. A Clinical Phase II Study to Assess Efficacy, Safety, and Tolerability of Waterfree Cyclosporine Formulation for Treatment of Dry Eye Disease.
Wirta DL; Torkildsen GL; Moreira HR; Lonsdale JD; Ciolino JB; Jentsch G; Beckert M; Ousler GW; Steven P; Krösser S
Ophthalmology; 2019 Jun; 126(6):792-800. PubMed ID: 30703441
[TBL] [Abstract][Full Text] [Related]
14. Erratum: A restrictive dose of crystalloids in patients during laparoscopic cholecystectomy is safe and cost-effective: prospective, two-arm parallel, randomized controlled trial [Corrigendum].
Ther Clin Risk Manag; 2018; 14():1155. PubMed ID: 29983570
[TBL] [Abstract][Full Text] [Related]
15. Erratum: Retrospective analysis of relationships among the dose regimen, trough concentration, efficacy, and safety of teicoplanin in Chinese patients with moderate-severe Gram-positive infections [Corrigendum].
Infect Drug Resist; 2019; 12():431. PubMed ID: 30863125
[TBL] [Abstract][Full Text] [Related]
16. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group.
Sall K; Stevenson OD; Mundorf TK; Reis BL
Ophthalmology; 2000 Apr; 107(4):631-9. PubMed ID: 10768324
[TBL] [Abstract][Full Text] [Related]
17. Erratum: Efficacy and Safety of Retinol Palmitate Ophthalmic Solution in the Treatment of Dry Eye: A Japanese Phase II Clinical Trial [Corrigendum].
Drug Des Devel Ther; 2021; 15():813-816. PubMed ID: 33658762
[TBL] [Abstract][Full Text] [Related]
18. Erratum: Eribulin for the treatment of metastatic breast cancer: an update on its safety and efficacy [Corrigendum].
Int J Womens Health; 2015; 7():403. PubMed ID: 25960676
[TBL] [Abstract][Full Text] [Related]
19. Erratum: Effects of switching from olanzapine to aripiprazole on the metabolic profiles of patients with schizophrenia and metabolic syndrome: a double-blind, randomized, open-label study [Corrigendum].
Neuropsychiatr Dis Treat; 2015; 11():863. PubMed ID: 25848284
[TBL] [Abstract][Full Text] [Related]
20. Erratum: Efficacy and safety of indacaterol/glycopyrronium in Japanese patients with COPD: a subgroup analysis from the SHINE study [Corrigendum].
Int J Chron Obstruct Pulmon Dis; 2017; 12():231. PubMed ID: 28138232
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
